Tyra Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia

  In preclinical models, TYRA-300 demonstrated significant increases in growth and bone length-

-Phase 2 clinical study for pediatric achondroplasia planned to be initiated in 2024-
-Conference call and webcast today, March 1st, at 8:00 am ET-

TYRA will host a conference call and webcast today, March 1, 2023 at 8:00 a.m. ET. The conference call can be accessed by dialing 1-646-968-2525 for domestic callers and 1-888-596-4144 for international callers. Please provide the operator with the passcode 7533836 to join the conference call. The conference call will also be available via webcast under the "For Investors" section of TYRA's website at www.tyra.bio. An archive of the teleconference and webcast will also be made available on TYRA's website following the call.

https://finance.yahoo.com/news/tyra-biosciences-expands-development-tyra-120000901.html